Search results for "peripheral"

showing 10 items of 1028 documents

Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the arterial endothelium.

2012

Background Cigarette smoking is an important risk factor for the development of cardiovascular disease, yet the pathways through which this may operate are poorly understood. Therefore, the mechanism underlying cigarette smoke (CS)-induced arterial endothelial dysfunction and the potential link with fractalkine/CX3CL1 upregulation were investigated. Methods and results Stimulation of human arterial umbilical endothelial cells (HUAECs) with pathophysiological concentrations of CS extract (1% CSE) increased CX3CL1 expression. Neutralisation of CX3CL1 activity under dynamic flow conditions significantly inhibited CSE-induced mononuclear cell adhesion to HUAECs (67%). The use of small interferi…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEndotheliumPeripheral blood mononuclear cellMiceInternal medicineCX3CR1Cell AdhesionMedicineAnimalsHumansEndothelial dysfunctionRNA Small InterferingCell adhesionNADPH oxidasebiologybusiness.industryChemokine CX3CL1MicrocirculationSmokingNOX4Membrane ProteinsNADPH Oxidasesmedicine.diseaseUp-RegulationEndothelial stem cellmedicine.anatomical_structureEndocrinologyNADPH Oxidase 5Immunologybiology.proteinEndothelium VascularbusinessThorax
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct

The potential role of SP-D as an early biomarker of severity of asthma

2021

Surfactant decreases the surface tension of peripheral airways and modulates the immunological responses of the lung. The alterations of surfactant due to the airway inflammation suggest a role in the pathogenesis of asthma. We aim to test the hypothesis that serum levels of SP-A (Surfactant Protein A) and SP-D (Surfactant Protein-D) are altered in patients with mild asthma compared to healthy controls and those alterations are related to functional abnormalities of peripheral airways, which are an early marker of progression of asthma. In this pilot study, we recruited 20 mild asthmatics and 10 healthy controls. We measured serum SP-A and SP-D and all subjects underwent clinical, lung func…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyprecision medicinePilot ProjectsSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPathogenesisPulmonary surfactantInternal medicinemedicineHumansIn patientAsthmasmall airwaysLungbusiness.industryasthmaPulmonary Surfactant-Associated Protein Dmedicine.diseaserespiratory tract diseasesPeripheralSurfactant protein Amedicine.anatomical_structureBreath TestsBiomarker (medicine)businessBiomarkersJournal of Breath Research
researchProduct

Giant peripheral osteoma of the mandible simulating a parotid gland tumor

2019

Sin financiación 1.405 JCR (2019) Q3, 28/42 Otorhinolaringology 0.528 SJR (2019) Q2, 54/111 Otorhinolaryngology No data IDR 2019 UEV

RadiographyOdontologíaMandibleDiagnosis Differential03 medical and health sciences0302 clinical medicineX ray computedRadiography PanoramicHumansMedicineOsteomaAgedbusiness.industryMandibleOsteoma030206 dentistryAnatomyCáncermedicine.diseaseParotid NeoplasmsPeripheralParotid glandMandibular Neoplasmsmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisFemaleTomography X-Ray Computedbusiness
researchProduct

Using mRNA and small RNA gene expression changes in peripheral blood for easy detection of Ra-223 incorporation

2019

Radium-223Small RNARadiation analysisEnvironmental EngineeringmRNAlcsh:QR1-502Biologylcsh:Microbiologylcsh:PhysiologyIndustrial and Manufacturing EngineeringTranscriptomeProstate cancerRadium-223lcsh:ZoologyGene expressionmedicineradiation biomarkerssmall RNAincorporationlcsh:QL1-991Messenger RNAlcsh:QP1-981gene expression changesprostate cancermedicine.diseaseMolecular biologyPeripheral bloodtranscriptomemedicine.drugBIO Web of Conferences
researchProduct

Peripheral artery disease: potential role of ACE-inhibitor therapy

2008

Giuseppe Coppola, Giuseppe Romano, Egle Corrado, Rosa Maria Grisanti, Salvatore NovoDepartment of Internal Medicine, Cardiovascular and Nephro-Urological Diseases, Chair of Cardiovascular Disease, University of Palermo, Palermo, ItalyAbstract: Subjects with peripheral arterial disease (PAD) of the lower limbs are at high risk for cardiovascular and cerebrovascular events and the prevalence of coronary artery disease in such patients is elevated. Recent studies have shown that regular use of cardiovascular medications, such as therapeutic and preventive agents for PAD patients, seems to be promising in reducing long-term mortality and morbidity. The angiotensin-converting-enzyme (ACE) system…

Ramiprillcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyPathologyACE inhibitorsEndocrinology Diabetes and MetabolismBradykininAngiotensin-Converting Enzyme InhibitorsReviewDiseaseendothelial dysfunctionCoronary artery diseasechemistry.chemical_compoundperipheral arterial diseaseInternal medicineHumansMedicinePharmacology (medical)Endothelial dysfunctionCell ProliferationSubclinical infectionPeripheral Vascular Diseasesbusiness.industryFibrinolysisPublic Health Environmental and Occupational HealthCardiovascular AgentsPeripheral artery disease ACE-inhibitorintermittent claudicationHematologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolareperipheral arterial disease.Oxidative StressTreatment OutcomeLower ExtremitychemistryCardiovascular Diseaseslcsh:RC666-701ACE-inhibitorsACE inhibitorCardiovascular agentCardiologyEndothelium VascularatherosclerosisCardiology and Cardiovascular Medicinebusinessmedicine.drugVascular Health and Risk Management
researchProduct

Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.

2006

Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atherosclerotic disease alongside coronary heart disease (CHD) and cerebrovascular disease (CVD). Best medical treatment is beneficial even in patients who eventually need invasive treatment, as the safety, immediate success, and durability of intervention is greatly improved in patients who adhere to best medical treatment. In recent years, a number of studies have suggested that the ACE-inhibitor ramipril and different statins, together with antiplatelet drugs, reduce cardiovascular morbidity and mortality in PAD. Patients with PAD are really a category of patients with a very high cardiovascular risk…

Ramiprilmedicine.medical_specialtyRenal functionCoronary Diseasechemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesPeripheral Vascular DiseasesFramingham Risk ScoreCholesterolbusiness.industryAnticholesteremic AgentsGeneral MedicineArteriesCholesterol LDLIntermittent ClaudicationAtherosclerosisIntermittent claudicationPeripheralchemistryHemostasisCardiologyDisease Progressionmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsClaudicationbusinessmedicine.drugArchives of medical research
researchProduct

Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk

2019

Abstract Aims Studies have shown a non-linear relationship between systolic blood pressure (SBP) and diastolic blood pressure (DBP) and outcomes, with increased risk observed at both low and high blood pressure (BP) levels. We hypothesized that the BP-risk association is different in individuals with and without diabetes at high cardiovascular risk. Methods and results We identified patients with (N = 11 487) or without diabetes (N = 19 450), from 30 937 patients, from 133 centres in 44 countries with a median follow-up of 56 months in the ONTARGET/TRANSCEND studies. Patients had a prior history of stroke, myocardial infarction (MI), peripheral artery disease, or were high-risk diabetics. P…

Ramiprilmedicine.medical_specialtyhypertensionSystoleAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRamiprilDiastoleRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumanshigh cardiovascular riskTelmisartan030212 general & internal medicineMyocardial infarctionStrokeRetrospective StudiesHeart Failurediabetesbusiness.industryHazard ratioblood pressureBlood Pressure Determinationmedicine.diseasestrokeHospitalizationmyocardial infarctionBlood pressureCardiovascular DiseasesCase-Control StudiesHeart failureCardiologyDrug Therapy CombinationTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drugEuropean Heart Journal
researchProduct

Lymphocyte subset reference values in peripheral blood: European survey

1992

Reference valuesImmunologyCell BiologyGeneral MedicineBiologyPeripheral bloodLymphocyte subsetsBiology of the Cell
researchProduct

The effect of fractal contact lenses on peripheral refraction in myopic model eyes.

2014

Purpose: To test multizone contact lenses in model eyes: Fractal Contact Lenses (FCLs), designed to induce myopic peripheral refractive error (PRE). Methods: Zemax ray-tracing software was employed to simulate myopic and accommodation-dependent model eyes fitted with FCLs. PRE, defined in terms of mean sphere M and 90–180 astigmatism J180, was computed at different peripheral positions, ranging from 0 to 35 in steps of 5, and for different pupil diameters (PDs). Simulated visual performance and changes in the PRE were also analyzed for contact lens decentration and model eye accommodation. For comparison purposes, the same simulations were performed with another commercially available conta…

Refractive errorMaterials scienceAstigmatismProsthesis DesignRefraction OcularModels BiologicalPupilMyopia progressionCellular and Molecular NeuroscienceFractalOpticsmedicineMyopiaHumansContact lensesZemaxbusiness.industryModel eyesPeripheral refractionAccommodation Ocularmedicine.diseaseContact Lenses HydrophilicRefractionSensory SystemsContact lensOphthalmologyFractalsFISICA APLICADAVisual FieldsbusinessAccommodationCurrent eye research
researchProduct